Zurück
finance.yahoo.com/news/...s-fourth-quarter-full-210100908.html
quotes.morningstar.com/stock/depo/s?t=DEPO
finance.yahoo.com/q/pr?s=DEPO+Profile
quotes.morningstar.com/stock/depo/s?t=DEPO
finance.yahoo.com/q/pr?s=DEPO+Profile
Top-News
Depomed - FDA entscheid f. Blockbuster im Januar
Beiträge: 59
Zugriffe: 41.067 / Heute: 1
Zugriffe: 41.067 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Japan UCITS ETF 1D
Perf. 12M: +155,87%
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +66,44%
Xtrackers Artificial Intelligence and Big Data UCITS ETF 1C
Perf. 12M: +56,12%
Xtrackers S&P 500 2x Leveraged Daily Swap UCITS ETF 1C
Perf. 12M: +48,99%
Xtrackers MSCI USA Communication Services UCITS ETF 1D
Perf. 12M: +48,21%
Depomed ist wohl die beste biotechaktie,die ich je empfohlen habe,mittlerweile 1,5 MRd wert mit einem Kurs von 25 dollar,Tendenz stark steigend !!!
Wie sieht es aus bei euch,wer ist noch dabei ? Bierro,was ist mit dir ?
MFG
Chali
Wie sieht es aus bei euch,wer ist noch dabei ? Bierro,was ist mit dir ?
MFG
Chali
www.prnewswire.com/news-releases/...sing-appeal-300064544.html
sher gute Nachrichten für Depomed,aber nicht mehr für mich,denn ich habe meinen Gewinn realisiert,Depomed wird sicher weitersteigen,vor allem wenn mal irgendwann die Parkinson Geschichte weiterentwickelt und taugen sollte ...
MFG
Chali
MFG
Chali
www.marketwired.com/press-release/...n-nasdaq-hznp-2035930.htm
www.reuters.com/article/2015/07/07/...0150707?type=companyNews
hoffe du bist noch drin chalif! ;-)
www.reuters.com/article/2015/07/07/...0150707?type=companyNews
hoffe du bist noch drin chalif! ;-)
Bin hier seit Gestern auch dabei,wie ist eure momentane Meinung zu Depomed und zum Kursziel?
Horizon Pharma plc Increases Offer for Depomed, Inc. to $33.00 per Share
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that it has increased the value of its all-stock acquisition proposal to $33.00 per share from $29.25 per share, contingent on Depomed entering into good faith discussions regarding a transaction. The increased offer represents a 60 percent premium to the closing price of Depomed on July 6, 2015, the day prior to when Horizon's initial proposal was made public.
"Based on discussions we've had with Depomed's largest shareholders as well as our own shareholders, it is clear that they and the investment community strongly support a combination of our two businesses," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "We are resolute in our commitment to acquire Depomed and we call upon Depomed's board of directors to listen to their shareholders, fulfill their fiduciary responsibilities and meet with us in order to promptly complete a negotiated transaction."
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that it has increased the value of its all-stock acquisition proposal to $33.00 per share from $29.25 per share, contingent on Depomed entering into good faith discussions regarding a transaction. The increased offer represents a 60 percent premium to the closing price of Depomed on July 6, 2015, the day prior to when Horizon's initial proposal was made public.
"Based on discussions we've had with Depomed's largest shareholders as well as our own shareholders, it is clear that they and the investment community strongly support a combination of our two businesses," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "We are resolute in our commitment to acquire Depomed and we call upon Depomed's board of directors to listen to their shareholders, fulfill their fiduciary responsibilities and meet with us in order to promptly complete a negotiated transaction."
epomed, Inc. (NASDAQ:DEPO) Given a $10.00 Price Target at Royal Bank Of Canada
Posted by Stefani Robinson on Oct 30th, 2017 // No Comments
Depomed, Inc. logoRoyal Bank Of Canada set a $10.00 target price on Depomed, Inc. (NASDAQ:DEPO) in a report published on Friday, October 20th. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.
Several other equities analysts have also recently commented on the company. Piper Jaffray Companies set a $9.00 target price on Depomed and gave the company a hold rating in a research note on Sunday, October 15th. Mizuho reaffirmed a neutral rating and issued a $6.00 target price (down from $11.00) on shares of Depomed in a research report on Friday, October 13th. ValuEngine lowered Depomed from a sell rating to a strong sell rating in a research report on Thursday, September 28th. Morgan Stanley lowered Depomed from an equal weight rating to an underweight rating and lowered their price target for the company from $12.00 to $5.00 in a report on Tuesday, August 8th. Finally, Janney Montgomery Scott lowered Depomed from a buy rating to a neutral rating and lowered their price target for the company from $18.00 to $8.00 in a report on Tuesday, August 8th. Four analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the stock. The company has an average rating of Hold and an average target price of $12.74.
Get Depomed Inc. alerts:
Shares of Depomed (DEPO) opened at 4.88 on Friday. The stock’s market capitalization is $307.38 million. The firm has a 50-day moving average of $5.74 and a 200 day moving average of $8.77. Depomed has a 52-week low of $4.77 and a 52-week high of $24.00.
Depomed (NASDAQ:DEPO) last issued its earnings results on Monday, August 7th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.09 by ($0.52). The firm had revenue of $100.00 million for the quarter, compared to analysts’ expectations of $100.40 million. Depomed had a negative return on equity of 45.03% and a negative net margin of 26.02%. The firm’s revenue for the quarter was down 14.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.27 EPS. Equities research analysts forecast that Depomed will post $0.44 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System grew its holdings in Depomed by 0.4% in the 2nd quarter. Louisiana State Employees Retirement System now owns 25,400 shares of the specialty pharmaceutical company’s stock valued at $273,000 after buying an additional 100 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Depomed by 0.6% during the 2nd quarter. Arizona State Retirement System now owns 32,521 shares of the specialty pharmaceutical company’s stock worth $349,000 after purchasing an additional 200 shares in the last quarter. Texas Permanent School Fund grew its holdings in shares of Depomed by 1.1% during the 2nd quarter. Texas Permanent School Fund now owns 45,478 shares of the specialty pharmaceutical company’s stock worth $488,000 after purchasing an additional 517 shares in the last quarter. Nationwide Fund Advisors grew its holdings in shares of Depomed by 1.5% during the 2nd quarter. Nationwide Fund Advisors now owns 35,938 shares of the specialty pharmaceutical company’s stock worth $386,000 after purchasing an additional 533 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan grew its holdings in shares of Depomed by 4.2% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 14,660 shares of the specialty pharmaceutical company’s stock worth $157,000 after purchasing an additional 590 shares in the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.
Posted by Stefani Robinson on Oct 30th, 2017 // No Comments
Depomed, Inc. logoRoyal Bank Of Canada set a $10.00 target price on Depomed, Inc. (NASDAQ:DEPO) in a report published on Friday, October 20th. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.
Several other equities analysts have also recently commented on the company. Piper Jaffray Companies set a $9.00 target price on Depomed and gave the company a hold rating in a research note on Sunday, October 15th. Mizuho reaffirmed a neutral rating and issued a $6.00 target price (down from $11.00) on shares of Depomed in a research report on Friday, October 13th. ValuEngine lowered Depomed from a sell rating to a strong sell rating in a research report on Thursday, September 28th. Morgan Stanley lowered Depomed from an equal weight rating to an underweight rating and lowered their price target for the company from $12.00 to $5.00 in a report on Tuesday, August 8th. Finally, Janney Montgomery Scott lowered Depomed from a buy rating to a neutral rating and lowered their price target for the company from $18.00 to $8.00 in a report on Tuesday, August 8th. Four analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the stock. The company has an average rating of Hold and an average target price of $12.74.
Get Depomed Inc. alerts:
Shares of Depomed (DEPO) opened at 4.88 on Friday. The stock’s market capitalization is $307.38 million. The firm has a 50-day moving average of $5.74 and a 200 day moving average of $8.77. Depomed has a 52-week low of $4.77 and a 52-week high of $24.00.
Depomed (NASDAQ:DEPO) last issued its earnings results on Monday, August 7th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.09 by ($0.52). The firm had revenue of $100.00 million for the quarter, compared to analysts’ expectations of $100.40 million. Depomed had a negative return on equity of 45.03% and a negative net margin of 26.02%. The firm’s revenue for the quarter was down 14.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.27 EPS. Equities research analysts forecast that Depomed will post $0.44 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System grew its holdings in Depomed by 0.4% in the 2nd quarter. Louisiana State Employees Retirement System now owns 25,400 shares of the specialty pharmaceutical company’s stock valued at $273,000 after buying an additional 100 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Depomed by 0.6% during the 2nd quarter. Arizona State Retirement System now owns 32,521 shares of the specialty pharmaceutical company’s stock worth $349,000 after purchasing an additional 200 shares in the last quarter. Texas Permanent School Fund grew its holdings in shares of Depomed by 1.1% during the 2nd quarter. Texas Permanent School Fund now owns 45,478 shares of the specialty pharmaceutical company’s stock worth $488,000 after purchasing an additional 517 shares in the last quarter. Nationwide Fund Advisors grew its holdings in shares of Depomed by 1.5% during the 2nd quarter. Nationwide Fund Advisors now owns 35,938 shares of the specialty pharmaceutical company’s stock worth $386,000 after purchasing an additional 533 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan grew its holdings in shares of Depomed by 4.2% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 14,660 shares of the specialty pharmaceutical company’s stock worth $157,000 after purchasing an additional 590 shares in the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.
www.analystratings.com/articles/...heir-buy-rating-on-depomed/
|
Neueste Beiträge aus dem Depomed Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
4 | 58 | Depomed - FDA entscheid f. Blockbuster im Januar | Chalifmann3 | Balu4u | 25.04.21 01:42 |
